Bayer and Exscientia, the UK-based AI-driven drug discovery company, together aim to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.
Exscientia will initially work on three projects with targets agreed between both parties. It may be eligible to receive up to €240 million, including upfront and research payments, near term and clinical milestones. As part of the agreement, it may also receive sales royalties.
As part of this collaboration, Exscientia will apply its Centaur Chemist AI drug discovery platform to go beyond conventional human endeavour by using its evolutionary computing and deep learning algorithms to discover and optimise novel drug candidates at unprecedented productivity.
“Since our pioneering Nature papers demonstrating the automated design of small-molecules, we have enhanced our platform and exemplified it commercially, by accelerating the discovery of future drug molecules with partners,” said Professor Andrew Hopkins, CEO of Exscientia.